Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Homo sapiens | APEX nuclease (multifunctional DNA repair enzyme) 1 | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 0.4247 | 0.4247 |
Toxoplasma gondii | exonuclease III APE | 0.0023 | 0.0638 | 0.5 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0023 | 0.0638 | 0.5 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0023 | 0.0638 | 0.0638 |
Brugia malayi | hypothetical protein | 0.0043 | 0.4247 | 0.4247 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0023 | 0.0638 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.7163 | 0.7163 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.7163 | 0.7163 |
Brugia malayi | TAR-binding protein | 0.0076 | 1 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0023 | 0.0638 | 0.5 |
Schistosoma mansoni | ap endonuclease | 0.0023 | 0.0638 | 0.0638 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.4247 | 1 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0023 | 0.0638 | 0.5 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0.0638 | 0.5 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.3848 | 0.3848 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0023 | 0.0638 | 0.5 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0023 | 0.0638 | 0.5 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 0.4247 | 0.4247 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.4247 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 0.4247 | 0.4247 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0023 | 0.0638 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.4247 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.4247 | 1 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.3848 | 0.3848 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0023 | 0.0638 | 0.0638 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 1 | 1 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0023 | 0.0638 | 0.5 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0023 | 0.0638 | 0.0638 |
Schistosoma mansoni | ap endonuclease | 0.0023 | 0.0638 | 0.0638 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.7163 | 0.7163 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0023 | 0.0638 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.3848 | 0.3848 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.7163 | 0.7163 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0.0638 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 1 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 1 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0023 | 0.0638 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0023 | 0.0638 | 0.5 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 0.4247 | 0.4247 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0023 | 0.0638 | 0.0638 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.2239 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 0.4611 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | = 6.3096 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 7.0795 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 13.1154 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Vif-A3F Interactions: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (functional) | = 50.1187 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease. (Class of assay: confirmatory) [Related pubchem assays: 997 ] | ChEMBL. | No reference |
Potency (functional) | = 50.1187 um | PUBCHEM_BIOASSAY: qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease. (Class of assay: confirmatory) [Related pubchem assays: 1467, 2100, 2112, 1473, 1466 ] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.